Metformin plus lifestyle interventions can prevent diabetes in people with impaired glucose tolerance, treat type 2 diabetes ...

Eli Lilly explores expanding its weight-loss drugs, Mounjaro and Zepbound, to individuals with a BMI below 27 to prevent ...

In a groundbreaking move, Eli Lilly LLY is set to test its weight-loss medications on individuals who are not overweight but are at risk of gaining weight.

By integrating ultra-rapid acting insulin such as Lyumjev, which responds faster than traditional insulin, Tandem Diabetes ...

From Eli Lilly to Karuna Therapeutics to current owner Bristol Myers Squibb, the newly approved schizophrenia drug had quite ...

Aurobindo Pharma receives USFDA approval for Cephalexin tablets, expected to launch in Q3FY25 with CGT designation.

Aurobindo Pharma gains FDA approval for Cephalexin Tablets, bioequivalent to Keflet, with CGT designation and shared exclusivity.

The startup will be headed by CEO Ron Renaud, who previously led Cerevel Therapeutics — a developer of drugs for neurological conditions — and oversaw its acquisition by AbbVie in an $8.7 billion deal ...

Six 2025 Lilly Endowment Community Scholar finalists have been selected by the Steuben County Community Foundation, it was ...

This post was written and published as a collaboration between the in-house editorial team at Benzinga and Corp. with ...

Plus: Adam Frisch and Jeff Hurd debate for a second time. State-level super PAC spending on legislative races.

Eli Lilly is considering testing its blockbuster weight-loss drugs in people who are not overweight but are at risk of weight ...